"In our experience, we have found it beneficial to collect the liquid biopsy at the time of the initial tissue diagnosis if NSCLC is suspected by bedside pathology with rapid onsite evaluation (ROSE). The blood is stored by the company that operates the assay at no cost to the patient or the institution. Once a final pathologic diagnosis is rendered, the liquid biopsy is evaluated for genomic abnormalities and reported back within 3 business days." - Durrett S et al. Clinical Pulmonary Medicine: March 2018; 25(2):33–38
Topics: lung cancer prognosis, In the News, OCM, OCM quality measures